CUSIP: 464288836
Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / U.S. PHARMA ETF
-
Total 13F shares
-
6,485,331
-
Share change
-
+1,766,077
-
Total reported value
-
$550,147,201
-
Price per share
-
$84.83
-
Number of holders
-
179
-
Value change
-
+$150,318,415
-
Number of buys
-
97
-
Number of sells
-
39
Security key
464288836
Report period
Q4 2025
Institutions
179
Top holders
10
Reporting periods
Holder history for CUSIP 464288836
Recent filing periods:
Top shareholders of IHE - ISHARES TR - U.S. PHARMA ETF (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Institutional Holders of ISHARES TR - U.S. PHARMA ETF (IHE) as of Q4 2025
As of 31 Dec 2025,
ISHARES TR - U.S. PHARMA ETF (IHE) was held by
179 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,485,331 shares.
The largest 10 holders included
Fisher Asset Management, LLC, FOUNDATIONS INVESTMENT ADVISORS, LLC, MORGAN STANLEY, BANK OF AMERICA CORP /DE/, JPMORGAN CHASE & CO, ROYAL BANK OF CANADA, LPL Financial LLC, Anfield Capital Management, LLC, BNP PARIBAS FINANCIAL MARKETS, and GOLDMAN SACHS GROUP INC.
This page lists
179
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
Compare Q4 2025 vs Q3 2025 Across Filers
| Investor |
Q3 2025 Shares |
Q4 2025 Shares |
Share Diff |
Share Chg % |
Q3 2025 Value $ |
Q4 2025 Value $ |
Value Diff $ |
Value Chg % |
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.